Press release
Heart Failure Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Clinical Trials by DelveInsight | Abbott, Berlin Heart GmbH, Biotronik, Boston Scientific Corp, Jarvik Heart Inc., Lepu Medical
"Heart Failure Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Heart Failure Market.
The Heart Failure Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Heart Failure Pipeline Report: https://www.delveinsight.com/sample-request/heart-failure-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Heart Failure treatment therapies with a considerable amount of success over the years.
• Heart Failure companies working in the treatment market are Tenaya Therapeutics, Athersys, TransThera Biosciences, SalubrisBio, Ionis Pharmaceuticals, Arena Pharmaceuticals, Palatin Technologies, Bayer HealthCare, Eli Lilly and Company, and others, are developing therapies for the Heart Failure treatment
• Emerging Heart Failure therapies in the different phases of clinical trials are- TN-301, Invimestrocel, TT-00920, JK-07, IONIS AGT LRx, APD418, PL-3994, Finerenone, Tirzepatide, and others are expected to have a significant impact on the Heart Failure market in the coming years.
• In April 2024, The EMPACT-MI phase III clinical trial demonstrated a 10% relative risk reduction in the primary composite endpoint of time to first hospitalization due to heart failure or all-cause mortality for Jardiance® (empagliflozin) compared to placebo, though the results did not achieve statistical significance. Jardiance was administered to adults within 14 days of an acute myocardial infarction (heart attack) and showed a reassuring safety profile among this patient group.
• In January 2024, Bayer and its subsidiary Asklepios BioPharmaceutical (AskBio) have initiated the Phase II clinical trial for AB-1002, an investigational gene therapy aimed at treating congestive heart failure (CHF). This trial aims to evaluate the efficacy and safety of AB-1002 in adults diagnosed with non-ischemic cardiomyopathy, specifically those classified as NYHA Class III Heart Failure. Known as Gene PHosphatase Inhibition Therapy (GenePHIT), the study is a multicenter, double-blind, adaptive, placebo-controlled, randomized trial designed to assess the effects of a single intracoronary dose of AB-1002.
• In September 2023, Bayer has initiated three investigator-sponsored Phase III clinical trials to assess Kerendia (finerenone) for treating heart failure. Kerendia, a top-selling drug for Bayer, generated €67 million ($72.6 million) in sales in Q2 2023 according to the company's half-year report. GlobalData projects that sales could reach $1.4 billion by 2029.
Heart Failure Overview
Heart failure is a chronic medical condition where the heart muscle is unable to pump blood efficiently enough to meet the body's needs for oxygen and nutrients. This can result from various underlying conditions that weaken or damage the heart, such as coronary artery disease, high blood pressure, or previous heart attacks. Symptoms of heart failure include shortness of breath, fatigue, swelling in the legs, ankles, or abdomen, and difficulty exercising.
Get a Free Sample PDF Report to know more about Heart Failure Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/heart-failure-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Heart Failure Drugs Under Different Phases of Clinical Development Include:
• TN-301: Tenaya Therapeutics
• Invimestrocel: Athersys
• TT-00920: TransThera Biosciences
• JK-07: SalubrisBio
• IONIS AGT LRx: Ionis Pharmaceuticals
• APD418: Arena Pharmaceuticals
• PL-3994: Palatin Technologies
• Finerenone: Bayer HealthCare Pharmaceuticals
• Tirzepatide: Eli Lilly and Company
Heart Failure Route of Administration
Heart Failure pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
Heart Failure Molecule Type
Heart Failure Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule
Heart Failure Pipeline Therapeutics Assessment
• Heart Failure Assessment by Product Type
• Heart Failure By Stage and Product Type
• Heart Failure Assessment by Route of Administration
• Heart Failure By Stage and Route of Administration
• Heart Failure Assessment by Molecule Type
• Heart Failure by Stage and Molecule Type
DelveInsight's Heart Failure Report covers around 90+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Heart Failure product details are provided in the report. Download the Heart Failure pipeline report to learn more about the emerging Heart Failure therapies
https://www.delveinsight.com/sample-request/heart-failure-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Heart Failure Therapeutics Market include:
Key companies developing therapies for Heart Failure are - Abbott Laboratories, Berlin Heart GmbH, Biotronik SE & Co. KG, Boston Scientific Corporation, Jarvik Heart Inc., Lepu Medical Technology (Beijing)Co.,Ltd., Magenta Medical Ltd, MEDICO S.R.L., Medtronic PLC, Oscor, Inc., OSYPKA MEDICAL, Shree Pacetronix Ltd, and others.
Heart Failure Pipeline Analysis:
The Heart Failure pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Heart Failure with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Heart Failure Treatment.
• Heart Failure key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Heart Failure Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Heart Failure market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Heart Failure drugs and therapies
https://www.delveinsight.com/sample-request/heart-failure-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Heart Failure Pipeline Market Drivers
• Alongside these drug launches, a new therapeutic strategy is being explored, prevalence of chronic heart failure on the rise, strong collaboration between main stakeholders of therapeutic innovation: scientific community, industry and regulatory agencies are some of the important factors that are fueling the Heart Failure Market.
Heart Failure Pipeline Market Barriers
• However, true surrogate marker for mortality in heart failure (HF) remains elusive, high cost of approved therapies, transition of a clinical HFrEF project from one stage of development to the next is still associated with considerable development risk and other factors are creating obstacles in the Heart Failure Market growth.
Scope of Heart Failure Pipeline Drug Insight
• Coverage: Global
• Key Heart Failure Companies: Tenaya Therapeutics, Athersys, TransThera Biosciences, SalubrisBio, Ionis Pharmaceuticals, Arena Pharmaceuticals, Palatin Technologies, Bayer HealthCare, Eli Lilly and Company, and others
• Key Heart Failure Therapies: TN-301, Invimestrocel, TT-00920, JK-07, IONIS AGT LRx, APD418, PL-3994, Finerenone, Tirzepatide, and others
• Heart Failure Therapeutic Assessment: Heart Failure current marketed and Heart Failure emerging therapies
• Heart Failure Market Dynamics: Heart Failure market drivers and Heart Failure market barriers
Request for Sample PDF Report for Heart Failure Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/heart-failure-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Heart Failure Report Introduction
2. Heart Failure Executive Summary
3. Heart Failure Overview
4. Heart Failure- Analytical Perspective In-depth Commercial Assessment
5. Heart Failure Pipeline Therapeutics
6. Heart Failure Late Stage Products (Phase II/III)
7. Heart Failure Mid Stage Products (Phase II)
8. Heart Failure Early Stage Products (Phase I)
9. Heart Failure Preclinical Stage Products
10. Heart Failure Therapeutics Assessment
11. Heart Failure Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Heart Failure Key Companies
14. Heart Failure Key Products
15. Heart Failure Unmet Needs
16 . Heart Failure Market Drivers and Barriers
17. Heart Failure Future Perspectives and Conclusion
18. Heart Failure Analyst Views
19. Appendix
20. About DelveInsight
Related Reports:
Heart Failure Market https://www.delveinsight.com/report-store/heart-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Heart Failure Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Latest Reports:
Orthopedic Trauma Devices Market https://www.delveinsight.com/report-store/orthopedic-trauma-devices-market
Global Orthopedic Trauma Devices Market was valued at USD 7.01 billion in 2023, growing at a CAGR of 6.43% during the forecast period from 2024 to 2030 to reach USD 10.15 billion by 2030. The demand for orthopedic trauma devices is witnessing growth due to the rising number of accident and trauma cases, growing prevalence of degenerative bone disorders, the rising number of sports-related injuries, rising demand for technologically advanced products, and increasing geriatric population are expected to drive product demand in the global orthopedic trauma devices market.
Acute Ischemic Stroke Market
https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-market
DelveInsight's 'Acute Ischemic Stroke Market Insights, Epidemiology, and Market Forecast - 2032' report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of acute ischemic stroke in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Advanced Wound Care Market
https://www.delveinsight.com/report-store/advanced-wound-care-market
As per DelveInsight, the global Advanced Wound Care Market was valued at USD 10.44 billion in 2023, growing at a CAGR of 10.82% during the forecast period from 2024 to 2030, to reach USD 19.29 billion by 2030. The demand for advanced wound care is predominantly associated with the rising incidence of chronic wounds associated with various chronic disorders such as diabetes, and cancer, and also with the rising incidence of active wounds comprising burns, and surgical wounds, among others
Alcohol Use Disorder Market
https://www.delveinsight.com/report-store/alcohol-use-disorder-market
DelveInsight's "Alcohol Use Disorder (AUD) Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of AUD, historical and forecasted epidemiology, as well as the AUD market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
DelveInsight's "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), historical and forecasted epidemiology as well as the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Congestive Heart Failure Market
https://www.delveinsight.com/report-store/congestive-heart-failure-market
DelveInsight's "Congestive Heart Failure Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of CHF, historical and forecasted epidemiology as well as the CHF market trends in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan.
CDMO Market
https://www.delveinsight.com/report-store/contract-development-manufacturing-organization-market
Global CDMO market was valued at USD 100.02 billion in 2021, growing at a CAGR of 6.25% during the forecast period from 2024 to 2030, in order to reach USD 143.87 billion by 2030. Factors such as rising prevalence of various chronic and acute diseases leading to growing requirement of drugs, rising popularity of biologics as a treatment option are further expected to drive the demand for services offered by CDMOs as biologics being more complex than small molecules require elaborate facilities for product development.
Duchenne Muscular Dystrophy Market
https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-market
DelveInsight's "Duchenne Muscular Dystrophy Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of Duchenne Muscular Dystrophy historical and forecasted epidemiology as well as the Duchenne Muscular Dystrophy market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Generalized Myasthenia Gravis Market
https://www.delveinsight.com/report-store/generalized-myasthenia-gravis-gmg-market
DelveInsight's 'Generalized Myasthenia Gravis Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the Generalized Myasthenia Gravis, historical and forecasted epidemiology as well as the market trends in the United States, EU-5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Heart Failure Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Clinical Trials by DelveInsight | Abbott, Berlin Heart GmbH, Biotronik, Boston Scientific Corp, Jarvik Heart Inc., Lepu Medical here
News-ID: 3573147 • Views: …
More Releases from DelveInsight Business Research
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Heart
Heart Healthy Foods and Supplements vs Heart Conditions
Heart conditions remain a major health concern worldwide, but the good news is that specific heart healthy foods and supplements can significantly improve cardiovascular health.
Scientific research has demonstrated that certain foods, nutrients and supplements support heart function, reduce inflammation, and lower the risk of heart disease.
Top Heart Healthy Foods
Fatty Fish - Salmon, mackerel, and sardines are rich in omega-3 fatty acids, which help lower blood pressure and reduce inflammation. A…
Centrifugal Heart Pumps Market | Abbott Laboratories, Abiomed, Berlin Heart, Car …
The global centrifugal heart pumps market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the centrifugal heart pumps market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
Heart disease and Heart Attacks - Kaffailham.gr
Καρδιολόγος Αθηνα - https://kaffailham.gr
When people talk about heart disease or heart attacks. The arteries that they are talking about are the arteries that actually provide blood to the heart. Remember the heart itself is a muscle. It itself needs oxygen. So you have these arteries right over here, the red tubes. Those are arteries. and then the blue ones are veins. They're taking the de-oxygenated blood away from the tissue…
Artificial Heart Implant Market May See a Big Move | Major Giants Jarvik Heart, …
The Latest survey report on Artificial Heart Implant Market sheds lights on changing dynamics of each of the subsegments of Industry. As the shift to value continues, Artificial Heart Implant organizations have the dual challenge of increasing interoperability to improve clinical performance and the patient experience. Some of the companies listed in the study from complete survey list are Medtronic, Boston Scientific, Abbott, Terumo, B.Braun, SynCardia, BiVACOR, CARMAT, ReinHeart TAH…
HEART PUMP DEVICES Market 2020 | SWOT Analysis By Top Players Abbott Laboratorie …
A detailed study on HEART PUMP DEVICES Market formulated by Brandessence Market Research, puts together a concise analysis of the growth factors impacting the current business scenario across assorted regions. Significant information pertaining to the industry's size, share, application, and statistics are also summed in the report in order to present an ensemble prediction. In addition, this report undertakes an accurate competitive analysis illustrating the status of market majors in…
Heart Pump Device Market - Potential Innovations 2025 | Terumo, Jarvik Heart
Heart Pump Device Market: Snapshot
Heart pump devices are essentially mechanical pumps playing the role of ventricular assist devices. These are surgically implanted and are used for temporarily supporting the functions of heart in people with weak heart or irregular blood flow. These devices are notably used as a bridge to cardiac transplantation for patients suffering with end stage heart failure. They can also be used in patients during and after…
